Lamotrigine Tablet
Product Images NDC 70518-1978

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lamotrigine (NDC 70518-1978). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

2d955155 686d 40cd 898e Df7d760247a5 789 2

Image shows four different Lamotrigine tablet imprints with dosage and color: 25 mg white oval tablets imprinted with 'U 111', 100 mg white tablets imprinted with 'U 112', 150 mg white tablets imprinted with 'U 113', and 200 mg light blue tablets imprinted with 'U 114'.*

FDA Label Image

Remedy_label (Remedy Label)

Lamotrigine 150 mg oral tablet label from RemedyRepack Inc. The label shows the drug name, strength of 150 mg, and quantity of 30 tablets. It includes an NDC number 70518-1978-00, manufacturing information indicating Unichem, Ghaziabad, India, and instructions to refer to the package insert for use directions. The label cautions to keep medication out of reach of children and provides storage temperature guidelines.*

FDA Label Image

Ad7af627 Ea4b 4a78 A71e Db1255416d1e 01

Chemical structure diagram of lamotrigine, showing its molecular composition with chlorine atoms, amino groups, and a triazine ring system, consistent with the active ingredient lamotrigine in the product.*

FDA Label Image

Ad7af627 Ea4b 4a78 A71e Db1255416d1e 02

A Kaplan-Meier survival plot showing failure probability (%) over weeks for Lamotrigine compared to Placebo. The graph includes censored data points marked with crosses and indicates higher failure probability in Placebo group over time compared to Lamotrigine.*

FDA Label Image

Ad7af627 Ea4b 4a78 A71e Db1255416d1e 03

A Kaplan-Meier failure probability curve showing the comparison of failure probability (%) over weeks for Lamotrigine versus placebo. The chart includes censored data points and indicates that Lamotrigine has a lower failure probability than placebo throughout the study period up to approximately 80 weeks.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.